AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04948164
Drug: sumatriptan 85mg and naproxen sodium 500mg
RxNorm normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
Trial: NCT04948164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg).
Trial: NCT03837743
Drug: DUR-928 Topical Solution
RxNorm normalized name: Nitro-Dur Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution containing active drug
Trial: NCT02205983
Drug: 1000 mg Acetaminophen
RxNorm normalized name: acetaminophen 1000 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
Trial: NCT03285308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously twice daily.
Trial: NCT03283761
Drug: 5-FU 1200 mg/m^2 x 2 D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
Trial: NCT03283761
Drug: Leucovorin 400 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Trial: NCT02029586
Drug: MB12066 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, 100mg bid
Trial: NCT02029586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, 100mg bid
Trial: NCT02299115
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid
Trial: NCT01459562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01442428
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
Trial: NCT01442428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin placebo
Trial: NCT00589329
Drug: erythromycin and metronidazole (antibiotics)
RxNorm normalized name: metronidazole and diloxanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days
Trial: NCT00589329
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and pill placebo
Trial: NCT00866190
Drug: SQ109
RxNorm normalized name: SQ109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
Trial: NCT00866190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
Trial: NCT00239044
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02912650
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
Trial: NCT02912650
Drug: Ibuprofen 250 mg
RxNorm normalized name: ibuprofen 250 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 caplets of Ibuprofen 125 mg
Trial: NCT02912650
Drug: Acetaminophen 650 mg
RxNorm normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of Acetaminophen 325 mg
Trial: NCT02912650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 caplets of Placebo
Trial: NCT00294463
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00294463
Drug: Estradiol + Medroxy Progesterone Acetate
RxNorm normalized name: ESTRADIOL/PROGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00525551
Drug: Placebo (NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mL 0.9% NaCl
Trial: NCT00345657
Drug: Niacin Extended Release/Lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635232
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules once daily for 12 weeks
Trial: NCT00635232
Drug: PS433540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (2 x 100 mg capsules) once daily for 12 weeks
Trial: NCT00635232
Drug: PS433540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (4 x 100 mg capsules) once daily for 12 weeks
Trial: NCT00635232
Drug: PS433540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg (8 x 100 mg capsules) once daily for 12 weeks
Trial: NCT00578669
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg once daily for 16 weeks
Trial: NCT00319982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator (double-blind allocation of study medication)
Trial: NCT00758680
Drug: MK-1006
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
Trial: NCT00758680
Drug: Comparator: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
Trial: NCT02565173
Drug: placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice per day in both eyes for 12 weeks.
Trial: NCT00943267
Drug: Endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
Trial: NCT00574912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
Trial: NCT00546364
Drug: Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Trial: NCT00546364
Drug: Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Trial: NCT02304627
Drug: insulin 338 (GIPET I)
RxNorm normalized name: insulin isophane, human Injectable Suspension [Humulin I]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
Trial: NCT02578030
Drug: SHP465 12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02578030
Drug: SHP465 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05896930
Drug: Rifampicin 35 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 35 mg/kg once daily on days 1-14.
Trial: NCT02636192
Drug: No Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study and participants did not receive any intervention in this study.
Trial: NCT02249312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04642651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
Trial: NCT00527865
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
Trial: NCT00527865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.
Trial: NCT02954263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04445363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose extension: Placebo
Trial: NCT01980966
Drug: MHAA549A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose
Trial: NCT01980966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose
Trial: NCT01293838
Drug: Cipralex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512
Trial: NCT02312908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill manufactured to mask clonazepam 0.5mg tablet
Trial: NCT01071187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00638027
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched tablets bid
Trial: NCT00293254
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
Trial: NCT00822406
Drug: homeopathic medicine
RxNorm normalized name: Homeopathic medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: individualized homeopathic medicine
Trial: NCT00822406
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo - 6 months
Trial: NCT00193466
Drug: CAMPTH-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00039026
Drug: AC2993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT00039026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Trial: NCT05256524
Drug: The effect of LMWH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantified by aFXa-levels
Trial: NCT02187055
Drug: Tofacitinib with methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Trial: NCT03202979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.
Trial: NCT00848107
Drug: treprostinil diethanolamine
RxNorm normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release tablet; BID dosing; up to 16 mg BID
Trial: NCT03627520
Drug: [14C]Sulfatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Sulfatinib with 100 µCi \[14C\]
Trial: NCT04509882
Drug: bear bile pill
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bear bile pill (15 pills) taken orally three times a day after meals with water.
Trial: NCT04509882
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(15 pills) taken orally three times a day after meals with water.
Trial: NCT02187055
Drug: Tofacitinib without methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Trial: NCT01783548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02923986
Drug: BP1001 (varying dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP1001 (varying dose)
Trial: NCT02923986
Drug: BP1001 (fixed dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP1001 (fixed dose)
Trial: NCT03682224
Drug: Bupivacaine-Epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
Trial: NCT00894101
Drug: [F-18] FLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
Trial: NCT01635218
Drug: Individualized homeopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
Trial: NCT01635218
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
Trial: NCT01635218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
Trial: NCT03791710
Drug: Topical Cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serial dressing with topical agents e.g Silver Sulphadiazine
Trial: NCT01207765
Drug: 90Y Zevalin
RxNorm normalized name: Zevalin KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
Trial: NCT03322735
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
Trial: NCT04500418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optically identical pills without CVC.
Trial: NCT01468818
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Trial: NCT02535871
Drug: IDP-121 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product: IDP-121 Lotion
Trial: NCT02535871
Drug: IDP-121 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Product: IDP-121 Vehicle Lotion
Trial: NCT01838668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules orally BID
Trial: NCT04040023
Drug: Iron and vitamin Deficiencies Correction Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation
Trial: NCT03849287
Drug: CKD-333, formula I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT03849287
Drug: CKD-333, formula II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug
Trial: NCT03849287
Drug: CKD-330, D090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Drug
Trial: NCT01330459
Drug: Hydrocodone/acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
Trial: NCT01330459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
Trial: NCT01330459
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg oral ibuprofen
Trial: NCT01231399
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01231399
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02483208
Drug: BAY81-8973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY81-8973 infusion to analyze pharmacokinetics
Trial: NCT00650208
Drug: Lamictal® Tablets 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x25mg, single dose fasting
Trial: NCT03204708
Drug: iv analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were given 100 ml of tramadol 30 minutes before extubation
Trial: NCT03657758
Drug: EPA and rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
Trial: NCT03657758
Drug: High dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To take high dose rosuvastatin (10mg/day) for ９ months.
Trial: NCT01759732
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV on day-3 and -2
Trial: NCT01777620
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
Trial: NCT00714961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plus acetylsalicylic acid (ASA)
Trial: NCT02936414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accept placebo(300 mg/tid)+SGAs monotherapy.
Trial: NCT00408954
Drug: UK-369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MR tablet once daily for 2 weeks
Trial: NCT00408954
Drug: UK-369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-369,003-100 mg MR formulation for 2 weeks
Trial: NCT00433537
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00433537
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02906761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets) twice daily for 6 months
Trial: NCT03893565
Drug: GSK2831781 - Double Blind Phase
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).